11/14
08:22 am
cyth
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/14
08:05 am
cyth
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
High
Report
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
9/6
08:09 pm
cyth
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARCH, CYTH, VGR on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARCH, CYTH, VGR on Behalf of Shareholders
9/5
09:18 am
cyth
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1) [Yahoo! Finance]
Medium
Report
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1) [Yahoo! Finance]
9/5
09:05 am
cyth
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
Medium
Report
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
8/27
09:16 am
cyth
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) had its "hold" rating re-affirmed by analysts at Maxim Group.
Medium
Report
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) had its "hold" rating re-affirmed by analysts at Maxim Group.
8/26
05:41 pm
cyth
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
Medium
Report
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
8/26
01:50 pm
cyth
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, CYTH, ARCH, CEIX on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, CYTH, ARCH, CEIX on Behalf of Shareholders
8/26
09:37 am
cyth
Kuehn Law Encourages CYTH, ARCH, CEIX, and VGR Investors to Contact Law Firm
Low
Report
Kuehn Law Encourages CYTH, ARCH, CEIX, and VGR Investors to Contact Law Firm
8/26
08:07 am
cyth
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) had its price target lowered by analysts at Ascendiant Capital Markets from $2.60 to $0.95. They now have a "buy" rating on the stock.
Medium
Report
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) had its price target lowered by analysts at Ascendiant Capital Markets from $2.60 to $0.95. They now have a "buy" rating on the stock.
8/23
01:05 pm
cyth
Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
Medium
Report
Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
8/23
08:09 am
cyth
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $0.95 price target on the stock, down previously from $3.00.
High
Report
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $0.95 price target on the stock, down previously from $3.00.
8/22
06:35 pm
cyth
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTH
High
Report
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTH